Implementing and Optimizing Universal Germline Genetic Testing for Patients With Prostate Cancer in Clinical Practice

Area of Science:

• Oncology
• Genetics
• Cancer Care

Background:

• Germline genetic testing (GGT) in prostate cancer is underutilized, creating disparities in accessing precision therapies and clinical trials.
• Existing guidelines and testing practices miss significant numbers of patients with pathogenic variants, particularly non-white individuals.
• Barriers like cost, access, and incomplete data hinder consistent GGT application in prostate cancer management.

Purpose of the Study:

• To advocate for universal germline genetic testing (UGGT) in all prostate cancer patients.
• To provide practical recommendations for the effective implementation of UGGT.
• To enhance equity and decision-making in prostate cancer care through widespread genetic assessment.

Main Methods:

• A consensus meeting of prostate cancer experts was convened in March 2024 to discuss UGGT implementation strategies.
• Review of current challenges in GGT utilization, including guideline adherence and identified disparities.
• Development of recommendations based on expert discussion for integrating UGGT into clinical practice.

Main Results:

• Recommendations for integrating UGGT into both oncology and urology practices were formulated.
• The study outlines strategies to overcome existing barriers to GGT in prostate cancer.
• Key considerations for successful UGGT implementation were identified.

Conclusions:

• Successful UGGT implementation requires careful gene panel selection and management of variants of uncertain significance.
• Appropriate genetics follow-up and seamless integration of test reports into electronic medical records are crucial.
• Addressing these details will maximize benefits and mitigate risks associated with UGGT in prostate cancer care.